Floatz logo

Sargramostim

Digestive System Neuroendocrine Neoplasm

Roswell Park Cancer Instituteprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the Digestive System Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
Oxodotreotide
National Cancer Institute (NCI)
Phase 4BBB
Octreotide Pamoate
Novartis Pharmaceuticals
Phase 3BB
EUDEMINE INJECTION
University of Maryland, Baltimore
Phase 4BB
Everolimus
RayzeBio, Inc.
Phase 3BB
DOTATOC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3B

View all 31 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →